PTX 7.14% 3.9¢ prescient therapeutics limited

I believe that the preference has always been to use Cell-Pryme...

  1. 5,844 Posts.
    lightbulb Created with Sketch. 17193
    I believe that the preference has always been to use Cell-Pryme A as a neoadjuvant.

    According to the patent, Cell-Pryme A should be administered at least 18 hours prior to CAR-T, dendritic cells or NK cells being administered.

    https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022241515&_cid=P11-LP80EH-30307-1
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
3.9¢
Change
-0.003(7.14%)
Mkt cap ! $31.40M
Open High Low Value Volume
4.0¢ 4.1¢ 3.9¢ $75.11K 1.897M

Buyers (Bids)

No. Vol. Price($)
2 355874 3.9¢
 

Sellers (Offers)

Price($) Vol. No.
4.0¢ 75 1
View Market Depth
Last trade - 15.59pm 19/06/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.